As GDNF is highly expressed in NSCLC [116], we could hypothesize in RET inhibitors resistant cancer cells harboring MET amplification, a cross-talking between tumor microenvironment and TK receptors. The gene discussed is MET; the disease is non-small cell lung carcinoma.